Effect of the direct renin Inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat
dc.contributor.author | Kedrah, Alla Eldeen | |
dc.contributor.author | Arı, Elif | |
dc.contributor.author | Alahdab, Yeşim | |
dc.contributor.author | Macunluoğlu, Beyza | |
dc.contributor.author | Atakan, Aydın | |
dc.contributor.author | Aşıcıoğlu, Ebru | |
dc.contributor.author | Çakalağaoğlu, Fulya | |
dc.contributor.author | Koç, Mehmet | |
dc.contributor.buuauthor | Gül, Cuma Bülent | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0003-2467-9356 | tr_TR |
dc.contributor.researcherid | A-7063-2018 | tr_TR |
dc.contributor.scopusid | 23988796000 | tr_TR |
dc.date.accessioned | 2022-05-20T05:48:56Z | |
dc.date.available | 2022-05-20T05:48:56Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Background: Renal vasoconstriction, activated by the reninangiotensin system, plays a pivotal role in the pathogenesis of contrast-induced nephropathy (CIN). The purpose of this study was to evaluate the effect of aliskiren, a direct renin inhibitor, for the prophylaxis of experimental CIN in the rat. Methods: Thirty-two Wistar albino rats were divided into four groups of 8 rats each, namely the control (C), aliskiren (A), contrast media (CM) and aliskiren plus contrast media (ACM) groups. Aliskiren was given orally at a dose of 50 mg/kg/day once daily for 5 consecutive days. CIN was induced by intravenous administration of indomethacin, N-nitro-L-arginine methyl ester and high-osmolar contrast medium meglumine amidotrizoate. Renal function parameters, kidney histology and tubular expression of vascular endothelial growth factor were determined. Results: Mean serum creatinine was significantly lower (p < 0.001) and mean creatinine clearance was higher (p < 0.001) in the ACM group compared with the CM group. However, there were no differences between the ACM and CM groups in terms of tubular necrosis, proteinaceous casts, medullary congestion and vascular endothelial growth factor expression. Conclusion: Our preliminary data seem to suggest a potential role of aliskiren for the prophylaxis of CIN in an experimental rat model. | en_US |
dc.description.sponsorship | Department of Nephrology, Marmara University School of Medicine, Istanbul, Turkey | en_US |
dc.identifier.citation | Kedrah, A. E. vd. (2012). "Effect of the direct renin Inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat". Kidney and Blood Pressure Research, 35(6), 425-430. | en_US |
dc.identifier.endpage | 430 | tr_TR |
dc.identifier.issn | 1420-4096 | |
dc.identifier.issn | 1423-0143 | |
dc.identifier.issue | 6 | tr_TR |
dc.identifier.pubmed | 22677784 | tr_TR |
dc.identifier.scopus | 2-s2.0-84861808237 | tr_TR |
dc.identifier.startpage | 425 | tr_TR |
dc.identifier.uri | https://doi.org/10.1159/000336104 | |
dc.identifier.uri | https://www.karger.com/Article/FullText/336104 | |
dc.identifier.uri | http://hdl.handle.net/11452/26537 | |
dc.identifier.volume | 35 | tr_TR |
dc.identifier.wos | 000314461100005 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karger | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | Kidney and Blood Pressure Research | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Physiology | en_US |
dc.subject | Urology & nephrology | en_US |
dc.subject | Cardiovascular system & cardiology | en_US |
dc.subject | Aliskiren | en_US |
dc.subject | Contrast-induced nephropathy | en_US |
dc.subject | Acute renal failure | en_US |
dc.subject | Experimental study | en_US |
dc.subject | Converting enzyme-inhibitors | en_US |
dc.subject | Blood-pressure | en_US |
dc.subject | Hypertension | en_US |
dc.subject | Blockade | en_US |
dc.subject | Media | en_US |
dc.subject.emtree | Aliskiren | en_US |
dc.subject.emtree | Arginine methyl ester | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Indometacin | en_US |
dc.subject.emtree | Meglumine diatrizoate | en_US |
dc.subject.emtree | Vasculotropin | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Contrast induced nephropathy | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Creatinine clearance | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | In vivo study | en_US |
dc.subject.emtree | Kdney medulla congestion | en_US |
dc.subject.emtree | Kidney disease | en_US |
dc.subject.emtree | Kidney function | en_US |
dc.subject.emtree | Kidney tubule necrosis | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Prophylaxis | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Rat | en_US |
dc.subject.emtree | Sodium excretion | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.mesh | Amides | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Contrast media | en_US |
dc.subject.mesh | Fumarates | en_US |
dc.subject.mesh | Kidney diseases | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Random allocation | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, wistar | en_US |
dc.subject.mesh | Renin | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.scopus | Percutaneous Coronary Intervention; Coronary Angiography; Kidney Diseases | en_US |
dc.subject.wos | Physiology | en_US |
dc.subject.wos | Urology & nephrology | en_US |
dc.subject.wos | Peripheral vascular disease | en_US |
dc.title | Effect of the direct renin Inhibitor aliskiren in the prevention of experimental contrast-induced nephropathy in the rat | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |